FDA Orange Book · active-ingredient family
Ertugliflozin; metformin hydrochloride
Ertugliflozin; metformin hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SEGLUROMET · NDA 209806
1
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SEGLUROMETRLD×4 | MSD SUB MERCK | NDA 209806 | — | Dec 19, 2017 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9439902 | Oct 21, 2030 | in 4 yr 5 mo | U-2214 |
| 9308204 | Oct 21, 2030 | in 4 yr 5 mo | Product |
| 8080580 | Dec 19, 2031 | in 5 yr 7 mo | SubstanceProductU-2214 |
Ertugliflozin; metformin hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

